SCHEMBL1292124

SCHEMBL1292124

CN1CCc2c(sc(NC(=O)c3ccc(S(=O)(=O)N(C)c4ccccc4)cc3)c2-c2nc3ccccc3s2)C1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APEX1 P27695 8/20 0.65
UHRF1 Q96T88 1/20 0.61
LMNA P02545 3/20 0.60
TP53 P04637 2/20 0.60
RXFP1 Q9HBX9 1/20 0.56
MEN1 O00255 6/20 0.55
KMT2A Q03164 6/20 0.55
CRHBP P24387 1/20 0.55
CRHR2 Q13324 1/20 0.55
KDM4E B2RXH2 2/20 0.53
HTT P42858 2/20 0.53
NPC1 O15118 1/20 0.53
USP2 O75604 1/20 0.53
POLB P06746 1/20 0.53
RECQL P46063 1/20 0.53
RAB9A P51151 1/20 0.53
BLM P54132 1/20 0.53
MYC P01106 1/20 0.52
ALDH1A1 P00352 1/20 0.50
MAPT P10636 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1292147 0.88 APEX1 (0.66) APEX1UHRF1LMNATP53RXFP1
SCHEMBL13833618 0.88 APEX1 (0.80) APEX1UHRF1LMNATP53RXFP1
SCHEMBL14209173 0.87 APEX1 (0.64) APEX1UHRF1LMNATP53RXFP1
SCHEMBL14209175 0.87 APEX1 (0.62) APEX1UHRF1LMNATP53RXFP1
SCHEMBL14209174 0.86 APEX1 (0.63) APEX1UHRF1LMNATP53RXFP1
SCHEMBL1292581 0.86 APEX1 (0.67) APEX1UHRF1LMNATP53RXFP1
SCHEMBL14209373 0.86 APEX1 (0.67) APEX1UHRF1LMNATP53RXFP1
SCHEMBL1292249 0.86 POLB (0.67) APEX1UHRF1LMNATP53RXFP1
SCHEMBL14209371 0.86 APEX1 (0.62) APEX1UHRF1LMNATP53RXFP1
SCHEMBL14233169 0.85 APEX1 (0.66) APEX1UHRF1LMNATP53RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1589970-A4 PHARMACEUTICAL COMPOSITIONS COMPRISING THIENO ¬2,3-C PYRIDINE DERITIVES AND USE THEREOF RIMONYX PHARMACEUTICALS LTD (IL) 2008-05-21 EP claimed
US-7365080-B2 2-[[4-[(4-methyl-1-piperazinyl)sulfonyl]benzoyl]amino]-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide; inhibiting interactions between effector cell adhesion molecules (ECAM), as selectins, and glycosaminoglycans (GAG), as heparan sulfate glycosaminoglycans (HS-GAGs); autoimmune diseases RIMONYX PHARMACEUTICALS LTD. (IL) 2008-04-29 US claimed
JP-2006516610-A 2006-07-06 JP claimed
US-20060135529-A1 Pharmaceutical compositions comprising thieno[2,3-c]pyridine derivatives and use thereof RIMONYX PHARMACEUTICALS LTD (IL) 2006-06-22 US claimed
EP-1589970-A2 PHARMACEUTICAL COMPOSITIONS COMPRISING THIENO [2,3-C]PYRIDINE DERITIVES AND USE THEREOF Rimonyx Pharmaceuticals Ltd. (IL) 2005-11-02 EP claimed
WO-2004069149-A2 PHARMACEUTICAL COMPOSITIONS COMPRISING THIENO[2,3-C]PYRIDINE DERIVATIVES AND USE THEREOF RIMONYX PHARMACEUTICALS LTD. (IL) 2004-08-19 WO claimed
WO-2012045114-A1 AGENTS AND METHODS FOR TREATING HEMATOLOGIC CONDITIONS THE UNIVERSITY OF QUEENSLAND (AU) 2012-04-12 WO disclosed
EP-1589970-A4 PHARMACEUTICAL COMPOSITIONS COMPRISING THIENO ¬2,3-C PYRIDINE DERITIVES AND USE THEREOF RIMONYX PHARMACEUTICALS LTD (IL) 2008-05-21 EP disclosed
US-7365080-B2 2-[[4-[(4-methyl-1-piperazinyl)sulfonyl]benzoyl]amino]-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide; inhibiting interactions between effector cell adhesion molecules (ECAM), as selectins, and glycosaminoglycans (GAG), as heparan sulfate glycosaminoglycans (HS-GAGs); autoimmune diseases RIMONYX PHARMACEUTICALS LTD. (IL) 2008-04-29 US disclosed
US-7365080-B2 2-[[4-[(4-methyl-1-piperazinyl)sulfonyl]benzoyl]amino]-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide; inhibiting interactions between effector cell adhesion molecules (ECAM), as selectins, and glycosaminoglycans (GAG), as heparan sulfate glycosaminoglycans (HS-GAGs); autoimmune diseases RIMONYX PHARMACEUTICALS LTD. (IL) 2008-04-29 US disclosed
US-7365080-B2 2-[[4-[(4-methyl-1-piperazinyl)sulfonyl]benzoyl]amino]-6-ethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxamide; inhibiting interactions between effector cell adhesion molecules (ECAM), as selectins, and glycosaminoglycans (GAG), as heparan sulfate glycosaminoglycans (HS-GAGs); autoimmune diseases RIMONYX PHARMACEUTICALS LTD. (IL) 2008-04-29 US disclosed
US-20060135529-A1 Pharmaceutical compositions comprising thieno[2,3-c]pyridine derivatives and use thereof RIMONYX PHARMACEUTICALS LTD (IL) 2006-06-22 US disclosed
EP-1589970-A2 PHARMACEUTICAL COMPOSITIONS COMPRISING THIENO [2,3-C]PYRIDINE DERITIVES AND USE THEREOF Rimonyx Pharmaceuticals Ltd. (IL) 2005-11-02 EP disclosed
WO-2004069149-A2 PHARMACEUTICAL COMPOSITIONS COMPRISING THIENO[2,3-C]PYRIDINE DERIVATIVES AND USE THEREOF RIMONYX PHARMACEUTICALS LTD. (IL) 2004-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135529-A1 Pharmaceutical compositions comprising thieno[2,3-c]pyridine derivatives and use thereof CD4, SELPLG, ITGAM APEX1 3872/4885UHRF1 4726/4885LMNA 2544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.